Investing.com - Century Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Century Therapeutics announced earnings per share of $-0.53 on revenue of $2.22M. Analysts polled by Investing.com EPS of $-0.59 on revenue of $1.06M.
Century Therapeutics 's are down 4.96% and is trading at $11.58 , still down 46.98% from its 52 week high of $21.84 set on Wednesday, November 10, 2021.
Century Therapeutics shares gained 15.11% to trade at $11.58 in intra-day trade the report.
Century Therapeutics follows other major Healthcare sector earnings this month
Century Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar